Soleno Therapeutics (NASDAQ:SLNO) Cut to “Hold” at TD Cowen

TD Cowen lowered shares of Soleno Therapeutics (NASDAQ:SLNO) from a buy rating to a hold rating in a research note published on Tuesday morning, MarketBeat reports. TD Cowen currently has $53.00 price objective on the stock, down from their previous price objective of $85.00.

Several other equities research analysts have also commented on the stock. HC Wainwright reduced their price target on shares of Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Wednesday, March 4th. Wells Fargo & Company reduced their price target on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen lowered shares of Soleno Therapeutics from a “buy” rating to a “hold” rating in a research report on Sunday, March 22nd. Finally, Oppenheimer reduced their price target on shares of Soleno Therapeutics from $110.00 to $80.00 and set an “outperform” rating for the company in a research report on Wednesday, March 18th. Four investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $89.20.

Soleno Therapeutics Stock Down 0.2%

SLNO stock opened at $52.51 on Tuesday. Soleno Therapeutics has a twelve month low of $29.43 and a twelve month high of $90.32. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. The firm has a market cap of $2.71 billion, a PE ratio of 228.31 and a beta of -2.81. The business has a 50 day moving average of $38.63 and a 200 day moving average of $47.86.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The firm had revenue of $91.73 million during the quarter, compared to the consensus estimate of $88.55 million. On average, research analysts forecast that Soleno Therapeutics will post -3.72 EPS for the current fiscal year.

Institutional Investors Weigh In On Soleno Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new position in shares of Soleno Therapeutics during the 2nd quarter valued at approximately $25,000. Danske Bank A S purchased a new position in shares of Soleno Therapeutics in the third quarter valued at $27,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Soleno Therapeutics in the third quarter valued at $37,000. Global Retirement Partners LLC grew its holdings in shares of Soleno Therapeutics by 519.0% in the fourth quarter. Global Retirement Partners LLC now owns 619 shares of the company’s stock valued at $29,000 after purchasing an additional 519 shares in the last quarter. Finally, Quarry LP purchased a new position in shares of Soleno Therapeutics in the third quarter valued at $47,000. 97.42% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Zacks and other outlets note a recent sharp rally tied to acquisition activity/sector M&A — reports point to a cash deal at $53/share as the catalyst that pushed SLNO higher in recent sessions, supporting a takeover premium argument. Soleno Therapeutics Stock Rallies 56.4% in a Week: Here’s Why
• Neutral Sentiment: Analysts’ sector commentary (Gilead/others including SLNO) provides context on competitive dynamics and product transfers in endocrinology/rare disease, useful for investors assessing strategic value. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: Multiple law firms have filed or solicited plaintiffs in a securities class action tied to alleged misstatements about SLNO’s Phase 3 program; a May 5, 2026 lead‑plaintiff deadline is driving outreach and increases perceived legal risk. Rosen Law Firm Encourages Soleno Investors to Secure Counsel
• Negative Sentiment: Additional firms (Faruqi & Faruqi, Bragar Eagel & Squire, Hagens Berman, Pomerantz, Bronstein Gewirtz & Grossman, Robbins Geller, Bernstein Liebhard, Glancy Prongay, Kahn Swick & Foti and others) are issuing notices and filings — the volume of solicitations amplifies headline risk and may pressure the stock while outcomes remain uncertain. Bragar Eagel & Squire Announces Class Action
• Negative Sentiment: Several brokerages (HC Wainwright, Piper Sandler, Robert W. Baird, Wolfe Research, TD Cowen, Cantor Fitzgerald, Lifesci Capital and others) downgraded SLNO or cut ratings/targets this week, reducing sell‑side support and contributing to downward momentum. Soleno Therapeutics Cut to “Hold” at Lifesci Capital

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.